Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/34829
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gürel, Ebru Gürevin | - |
dc.contributor.author | Kıyan, Hülya Tuba | - |
dc.contributor.author | Esener, Osman Behzat Burak | - |
dc.contributor.author | Üvez, Ayca | - |
dc.contributor.author | Ulukaya, Engin | - |
dc.contributor.author | Dimas, Konstantinos | - |
dc.contributor.author | Armutak, Elif İlkay | - |
dc.date.accessioned | 2023-11-09T12:26:03Z | - |
dc.date.available | 2023-11-09T12:26:03Z | - |
dc.date.issued | 2018-05-21 | - |
dc.identifier.citation | Gürel, G. E. vd. (2018). ''Chloroquine used in combination with chemotherapy synergistically suppresses growth and angiogenesis in vitro and in vivo''. Anticancer Research, 38(7), 4011-4020. | en_US |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.issn | 1791-7530 | - |
dc.identifier.uri | https://doi.org/10.21873/anticanres.12689 | - |
dc.identifier.uri | https://ar.iiarjournals.org/content/38/7/4011 | - |
dc.identifier.uri | http://hdl.handle.net/11452/34829 | - |
dc.description.abstract | Background: The inhibition of autophagy using pharmacological inhibitors such as chloroquine may be an effective strategy to overcome chemotherapy or resistance to anti-angiogenic therapy. Materials and Methods: The cytotoxic effect of doxorubicin (0.1-1 mu M), chloroquine (0.25-32 ,mu M) and their combination were investigated by employing ATP assay in human umbilical vein endothelial cells (HUVECs). The effect of doxorubicin and chloroquine combination was also measured using tube formation assay on Matrigel. The anti-angiogenic activities of doxorubicin (2.5 mu g/pellet) and chloroquine (15 mu g/pellet), their combination, and standards (50 mu g/pellet) were tested in vivo using the chick embryo chorioallantoic membrane (CAM) assay. Results: The combination of doxorubicin and chloroquine significantly had a stronger anti-angiogenic effect than the positive control (+/-)-thalidomide and doxorubicin alone in the CAM assay and in vitro tube-formation assay. Conclusion: Chloroquine enhanced the anti-angiogenic effect of doxorubicin on CAM at the tested concentrations. | en_US |
dc.description.sponsorship | İstanbul Üniversitesi - 49841 - 55089 - 21160 - 20856 - 49997 - 53382 | tr_TR |
dc.description.sponsorship | Kinik Company | en_US |
dc.language.iso | en | en_US |
dc.publisher | Int Inst Anticancer Research | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Oncology | en_US |
dc.subject | Doxorubicin | en_US |
dc.subject | Chloroquine | en_US |
dc.subject | Angiogenesis | en_US |
dc.subject | CAM assay | en_US |
dc.subject | Tube formation | en_US |
dc.subject | Chorioallantoic membrane | en_US |
dc.subject | Breast-cancer | en_US |
dc.subject | Cell-line | en_US |
dc.subject | Doxorubicin | en_US |
dc.subject | Therapy | en_US |
dc.subject | Model | en_US |
dc.subject | Inhibition | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Cardiotoxicity | en_US |
dc.subject | Nanoparticles | en_US |
dc.subject.mesh | Adenosine triphosphate | en_US |
dc.subject.mesh | Angiogenesis inhibitors | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antibiotics, antineoplastic | en_US |
dc.subject.mesh | Autophagy | tr_TR |
dc.subject.mesh | Cell proliferation | en_US |
dc.subject.mesh | Chick embryo | en_US |
dc.subject.mesh | Chloroquine | en_US |
dc.subject.mesh | Chorioallantoic membrane | en_US |
dc.subject.mesh | Doxorubicin | en_US |
dc.subject.mesh | Drug synergism | en_US |
dc.subject.mesh | Drug therapy, combination | en_US |
dc.subject.mesh | Human umbilical vein endothelial cells | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Neovascularization, pathologic | en_US |
dc.title | Chloroquine used in combination with chemotherapy synergistically suppresses growth and angiogenesis in vitro and in vivo | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000449943500028 | tr_TR |
dc.identifier.scopus | 2-s2.0-85049800874 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0001-5238-2432 | tr_TR |
dc.identifier.startpage | 4011 | tr_TR |
dc.identifier.endpage | 4020 | tr_TR |
dc.identifier.volume | 38 | tr_TR |
dc.identifier.issue | 7 | tr_TR |
dc.relation.journal | Anticancer Research | en_US |
dc.contributor.buuauthor | Aydınlık, Şeyma | - |
dc.contributor.researcherid | ABI-2909-2020 | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 29970525 | tr_TR |
dc.subject.wos | Oncology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 57190280044 | tr_TR |
dc.subject.scopus | Beclin 1; Chloroquine; Cancer Cell | en_US |
dc.subject.emtree | Chloroquine | en_US |
dc.subject.emtree | Cortisone | en_US |
dc.subject.emtree | Doxorubicin | en_US |
dc.subject.emtree | Prednisone | en_US |
dc.subject.emtree | Thalidomide | en_US |
dc.subject.emtree | Adenosine triphosphate | en_US |
dc.subject.emtree | Angiogenesis inhibitor | en_US |
dc.subject.emtree | Antineoplastic antibiotic | en_US |
dc.subject.emtree | Chloroquine | en_US |
dc.subject.emtree | Doxorubicin | en_US |
dc.subject.emtree | Antiangiogenic activity | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer chemotherapy | en_US |
dc.subject.emtree | Cancer inhibition | en_US |
dc.subject.emtree | Cell viability | en_US |
dc.subject.emtree | Chorioallantoic membrane assay | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug cytotoxicity | en_US |
dc.subject.emtree | Drug potentiation | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | In vitro study | en_US |
dc.subject.emtree | In vivo study | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Umbilical vein endothelial cell | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Autophagy | en_US |
dc.subject.emtree | Cell proliferation | en_US |
dc.subject.emtree | Chick embryo | en_US |
dc.subject.emtree | Chorioallantois | en_US |
dc.subject.emtree | Combination drug therapy | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Drug potentiation | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Neovascularization (pathology) | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Aydınlık_vd_2018.pdf | 618.5 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License